Pfizer Portfolio Changes: Q2 2026 Focus on Healthcare Sales
A detailed analysis of Pfizer Inc's portfolio holdings and changes during the second quarter of 2026, highlighting significant exits from ORIC Pharmaceuticals.
As part of its investment strategy oversight, Pfizer Inc's portfolio activities for the period ending June 30, 2026 (Q2 2026) have been examined. The analysis reveals specific changes in holdings during this quarter.
The most notable change occurred with ORIC PHARMACEUTICALS INC (ORIC). Pfizer disposed of a significant portion of its shares in ORIC, resulting in a nearly 92.2% decrease in the position during Q2 2026. This substantial reduction reflects a major sale activity within their portfolio for this quarter.
Despite this large exit from ORIC, Pfizer maintained or slightly adjusted several other positions throughout Q2 2026. Holdings like ALLOGENE THERAPEUTICS INC (ALLO), accounting for approximately 27.55% of the portfolio, and ARVINAS INC (ARVN) at around 16.24%, remained unchanged in terms of share count according to the disclosed data.
The investor's portfolio is overwhelmingly concentrated within the Healthcare sector, with holdings representing approximately 99.98% of the total value as of June 30, 2026. The remaining allocation, about 0.02%, consists of positions in sectors categorized as 'Unknown' based on the available information.
Other significant Healthcare holdings include CELCUITY INC (CELC), valued at roughly 17.35% of the portfolio, and several others like PYXIS ONCOLOGY INC (PYXS) (~11.43%), CARIBOU BIOSCIENCES INC (CRBU) (~4.63%), and smaller positions in companies such as SPERO THERAPEUTICS INC (SPRO), ZENTALIS PHARMACEUTICALS INC (ZNTL), and CARDIFF ONCOLOGY INC (CRDF).
It is important to note that the data provided does not indicate any other significant changes or purchases during this quarter. The sale of ORIC was the primary position adjustment disclosed, while all other listed holdings remained static in share count according to the available information.